매출 하락 → 마진 압박 → 현금 악화
Critical매출이 -33.5% 감소하며 영업이익률이 1.5%에서 -25.2%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.
Evidence
매출 YoY -33.5% (2023→2024)영업이익률 1.5%→-25.2%영업CF 8,193→-3,822
Alton
A123750 · KOSDAQ₩1,776-0.78%
2026-08-03 closeAlton — pricey right now, or cheap? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p
Beat the market on 62.1% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 150 화장품,의류,완구 peers · not investment advice
Valuation in its own history
PER — · PBR 1.13 — own history (2010-07~) percentiles 14/100 · 69/100
PER14/100
PBR69/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Grey zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 1.95
Distress
Grey
Safe
- Altman Z''
- 1.95
- Beneish M-Score
- -3.42
- Sloan accrual
- -8.24%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
4/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score4/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -14%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Margin trendWarning
영업이익률 악화 (1.5% → -25.2%, -26.7%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-03화장품,의류,완구
This stock is in 화장품,의류,완구: revenue rank 135 of 146, share 0%.
135 / 1460%revenue share
Who dominates this industry?
- 1효성티앤씨8.3%
- 2LG생활건강7.3%
- 3코웨이4.6%
- 4영원무역홀딩스4.6%
- 5미스토홀딩스4.6%
- 6알톤0%
Concentration
DistributedCR3 20.3%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
MixedDivergent lensesPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 1.85
- Direction
- 확대
- Level
- 좁음
- Years
- 8
Value lens
- P90/P10
- 8.6
- Median P/B
- 0.81
- Level
- 넓음
- n
- 140
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -25.2%
- Interest coverage
- -15.7x
- Return on equity (ROE)
- -31.6%
Operating margin −5pp
Operating lossInterest coverageBase -15.7x adverse case -18.9x
Return on equity (ROE)Base -31.6% adverse case -44.6%
Revenue −15%
Interest coverage riskInterest coverageBase -15.7x adverse case -13.4x
Return on equity (ROE)Base -31.6% adverse case -32.3%
Interest rate +2pp
Interest coverage riskInterest coverageBase -15.7x adverse case -10.7x
Return on equity (ROE)Base -31.6% adverse case -38.7%
Interest coverage limit
Already below the limit by 26.8ppInterest coverage limit at an operating margin of 1.6%
Interest expense coverage threshold
Financials at a glance
Alton's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 이녹스48.17%2026-07-22 · 증감 +2.80%p
- 나우IB7.76%2026-02-05 · 증감 +7.76%p
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- 이녹스첨단소재KRA272290 →
Shared holders: 이녹스
- 엘앤씨바이오KRA290650 →
Shared holders: 나우IB
Connections
AI-extracted related companies · for reference
Suppliers
시마노
Competitors
Recent filings
Alton's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Signal history (last ~2 years)
Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.
New MA alignment×2
26-04-02-26.6%26-03-26-13.6%
“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy